Diffusion of antipsychotics in the U.S. and French markets, 1998-2008

Psychiatric Services

Volumn 64, Issue 7, 2013, Pages 680-687

  Gallini, Adeline ^a   Donohue, Julie M ^b   Huskamp, Haiden A ^c  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUOXETINE; HALOPERIDOL; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PIMOZIDE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR MANIA; DEPRESSION; DRUG APPROVAL; DRUG FORMULATION; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; DRUG USE; FRANCE; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH PROMOTION; MAJOR DEPRESSION; PRESCRIPTION; PSYCHOSIS; SCHIZOPHRENIA; TREATMENT INDICATION; UNITED STATES; ADOLESCENT; ADULT; CHILD; CLASSIFICATION; CLINICAL PRACTICE; DRUG CONTROL; DRUG UTILIZATION; ECONOMICS; HUMAN; MASS COMMUNICATION; MENTAL DISORDERS; REIMBURSEMENT; STATISTICS AND NUMERICAL DATA; TRENDS; MENTAL DISEASE; STATISTICS;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CHILD; DIFFUSION OF INNOVATION; DRUG AND NARCOTIC CONTROL; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FRANCE; HUMANS; MENTAL DISORDERS; PHYSICIAN'S PRACTICE PATTERNS; REIMBURSEMENT MECHANISMS; UNITED STATES;

EID: 84883192391     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.004662012     Document Type: Article

References (36)

1. Alexander GC, Gallagher SA, Mascola A, et al: Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiology and Drug Safety 20:177-184, 2011
2. Leslie DL, Mohamed S, Rosenheck RA: Off-label use of antipsychotic medications in the Department of Veterans Affairs health care system. Psychiatric Services 60: 1175-1181, 2009
3. Leslie DL, Rosenheck R: Off-label use of antipsychotic medications in Medicaid. American Journal of Managed Care 18: e109-e117, 2012
4. Dorsey ER, Rabbani A, Gallagher SA, et al: Impact of FDA black box advisory on antipsychotic medication use. Archives of Internal Medicine 170:96-103, 2010
5. Morrato EH, Dodd S, Oderda G, et al: Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003. Clinical Therapeutics 29:183-195, 2007
6. Rosenheck RA, Leslie DL, Doshi JA: Policy implications of CATIE [Letter]. Psychiatric Services 59:695, 2008
7. Rosenheck RA, Leslie DL, Doshi JA: Second-generation antipsychotics: costeffectiveness, policy options, and political decision making. Psychiatric Services 59: 515-520, 2008
8. Ganguli R, Strassnig M: Are older antipsychotic drugs obsolete? British Medical Journal 332:1346-1347, 2006
9. Verdoux H, Tournier M, Bégaud B: Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatrica Scandinavica 121:4-10, 2010
10. Cáceres MC, Peñas-Lledó EM, de la Rubia A, et al: Increased use of second generation antipsychotic drugs in primary care: potential relevance for hospitalizations in schizophrenia patients. European Journal of Clinical Pharmacology 64: 73-76, 2008
11. Hayes J, Prah P, Nazareth I, et al: Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009. PLoS ONE 6:e28725, 2011
12. Prah P, Petersen I, Nazareth I, et al: National changes in oral antipsychotic treatment for people with schizophrenia in primary care between 1998 and 2007 in the United Kingdom. Pharmacoepidemiology and Drug Safety 21:161-169, 2012
13. Wu CS, Lin YJ, Feng J: Trends in treatment of newly treated schizophreniaspectrum disorder patients in Taiwan from 1999 to 2006. Pharmacoepidemiology and Drug Safety 21:989-996, 2012
14. World Health Report 2000: Health Systems: Improving Performance. Geneva, World Health Organization, 2000. Available at www.who.int/whr/2000/en/whr00-en. pdf
15. Cohen J, Faden L, Predaris S, et al: Patient access to pharmaceuticals: an international comparison. European Journal of Health Economics 8:253-266, 2007
16. Rodwin VG: The health care system under French national health insurance: lessons for health reform in the United States. American Journal of Public Health 93: 31-37, 2003
17. DeNavas Walt C, Proctor BD, Smith JC: Income, Poverty, and Health Insurance Coverage in the United States: 2010. Washington, DC, US Census Bureau, Sept 2011. Available at www.census.gov/prod/2011pubs/p60-239.pdf
18. Garfield RL, Zuvekas SH, Lave JR, et al: The impact of national health care reform on adults with severe mental disorders. American Journal of Psychiatry 168: 486-494, 2011
19. Grandfils N: Drug Price Setting and Regulation in France. DT no 16. Paris, Institut de recherché et documentation en économie de la santé, Sept 2008. Available at www.irdes.fr/EspaceAnglais/Publications/ Working Papers/DT16DrugPriceSettingRegulation France.pdf
20. Le Pen C: The drug budget silo mentality: the French case. Value in Health 6(suppl 1):S10-S19, 2003
21. Donohue JM, Huskamp HA, Zuvekas SH: Dual eligibles with mental disorders and Medicare part D: how are they faring? Health Affairs 28:746-759, 2009
22. Polinski JM, Wang PS, Fischer MA: Medicaid's prior authorization program and access to atypical antipsychotic medications. Health Affairs 26:750-760, 2007
23. Perronnin M, Pierre A, Rochereau T: Complementary Health Insurance in France: Wide-Scale Diffusion but Inequalities of Access Persist. Paris, Institut de recherché et documentation en économie de la santé, Jan 2011. Available at www.irdes.fr/EspaceAnglais/Publications/IrdesPublica tions/QES161.pdf
24. Hearne J: Prescription Drug Coverage Under Medicaid. Washington, DC, Congressional Research Service, Feb 6, 2008. Available at aging.senate.gov/crs/ medicaid 16.pdf
25. Lenderts S, Kalali AH: Average out-ofpocket expenses across different drug categories and commercial third-party payers. Psychiatry 7:12-13, 2010
26. Avis sur les médicaments. Saint-Denis La Plaine, France, Haute Autorité de santé. Available at www.has-sante.fr/portail/jcms/c- 5267/actes-medicaments-dispositifs-medicaux? cid=c-5267
27. Kovess V: The French Consensus Conference on long-term therapeutic strategies for schizophrenic psychoses. Social Psychiatry and Psychiatric Epidemiology 30: 49-52, 1995
28. Martin K, Bégaud B, Verdoux H, et al: Patterns of risperidone prescription: a utilization study in south-west France. Acta Psychiatrica Scandinavica 109:202-206, 2004
29. Goldman DP, Joyce GF, Zheng Y: Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 298: 61-69, 2007
30. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353: 1209-1223, 2005
31. Jones PB, Barnes TR, Davies L, et al: Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 63:1079-1087, 2006
32. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al: Consensus development conference on antipsychotic drugs and obesity and diabetes. Journal of Clinical Psychiatry 65: 267-272, 2004
33. Law MR, Ross-Degnan D, Soumerai SB: Effect of prior authorization of secondgeneration antipsychotic agents on pharmacy utilization and reimbursements. Psychiatric Services 59:540-546, 2008
34. Bailey RK, Adams JB, Unger DM: Atypical antipsychotics: a case study in new era risk management. Journal of Psychiatric Practice 12:253-258, 2006
35. Shi L, Ascher-Svanum H, Zhu B, et al: Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatric Services 58:482-488, 2007
36. Blin P, Olié JP, Sechter D, et al: Neuroleptic drug utilization among schizophrenic outpatients [in French]. Revue d'Epidemiologie et de Sante Publique 53:601-613, 2005